Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Regulatory oversight and safety of probiotic use.

Venugopalan V, Shriner KA, Wong-Beringer A.

Emerg Infect Dis. 2010 Nov;16(11):1661-5. doi: 10.3201/eid1611.100574.

2.

Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration.

Herbrecht R, Nivoix Y.

Clin Infect Dis. 2005 Jun 1;40(11):1635-7. Epub 2005 Apr 25. No abstract available.

PMID:
15889361
3.

[Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities].

Lestin F, Pertschy A, Rimek D.

Dtsch Med Wochenschr. 2003 Nov 28;128(48):2531-3. German.

PMID:
14648435
4.

Health-benefit claims for probiotic products.

Heimbach JT.

Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S122-4; discussion S144-51. doi: 10.1086/523327.

PMID:
18181716
5.
6.

Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use.

Martin IW, Tonner R, Trivedi J, Miller H, Lee R, Liang X, Rotello L, Isenbergh E, Anderson J, Perl T, Zhang SX.

Diagn Microbiol Infect Dis. 2017 Mar;87(3):286-288. doi: 10.1016/j.diagmicrobio.2016.12.004. Epub 2016 Dec 16.

PMID:
28024866
7.

[Saccharomyces cerevisiae fungemia in an elderly patient following probiotic treatment].

Eren Z, Gurol Y, Sonmezoglu M, Eren HS, Celik G, Kantarci G.

Mikrobiyol Bul. 2014 Apr;48(2):351-5. Turkish.

8.

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review.

Dendukuri N, Costa V, McGregor M, Brophy JM.

CMAJ. 2005 Jul 19;173(2):167-70. Review. Erratum in: CMAJ. 2005 Aug 16;173(4):345.

9.

Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis.

Cherifi S, Robberecht J, Miendje Y.

Acta Clin Belg. 2004 Jul-Aug;59(4):223-4.

PMID:
15597730
10.

Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum.

Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Magrini L, Di Somma S, Teggi A.

Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):143-6.

PMID:
24674691
11.

Probiotic foods and drugs: impact of US regulatory status on design of clinical trials.

Hibberd PL, Davidson L.

Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S137-40; discussion S144-51. doi: 10.1086/523321.

PMID:
18181720
12.

The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy.

Miller M.

Anaerobe. 2009 Dec;15(6):281-4. doi: 10.1016/j.anaerobe.2009.08.005. Epub 2009 Aug 20.

PMID:
19699309
13.

Saccharomyces cerevisiae fungemia: an emerging infectious disease.

Muñoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, Rincón C, Hortal J, Peláez T.

Clin Infect Dis. 2005 Jun 1;40(11):1625-34. Epub 2005 Apr 25. Review.

PMID:
15889360
14.

The US Food and Drug Administration and probiotics: regulatory categorization.

Degnan FH.

Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S133-6; discussion S144-51. doi: 10.1086/523324.

PMID:
18181719
16.

Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients.

Riquelme AJ, Calvo MA, Guzmán AM, Depix MS, García P, Pérez C, Arrese M, Labarca JA.

J Clin Gastroenterol. 2003 Jan;36(1):41-3.

PMID:
12488707
17.

Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.

Mattia A, Merker R.

Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S115-8; discussion S144-51. doi: 10.1086/523329.

PMID:
18181714
18.

Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment.

Appel-da-Silva MC, Narvaez GA, Perez LRR, Drehmer L, Lewgoy J.

Med Mycol Case Rep. 2017 Jul 25;18:15-17. doi: 10.1016/j.mmcr.2017.07.007. eCollection 2017 Dec.

19.

Saccharomyces boulardii fungemia caused by treatment with a probioticum.

Thygesen JB, Glerup H, Tarp B.

BMJ Case Rep. 2012 Mar 27;2012. pii: bcr0620114412. doi: 10.1136/bcr.06.2011.4412.

20.

Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii.

Segarra-Newnham M.

Ann Pharmacother. 2007 Jul;41(7):1212-21. Epub 2007 Jun 26. Review.

PMID:
17595306

Supplemental Content

Support Center